FierceBiotech Jan 26, 2026 'Things are looking up': British biotechs consider going public after yearslong IPO drought
FierceBiotech Jan 23, 2026 Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
FierceBiotech Jan 23, 2026 Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings
FierceBiotech Jan 23, 2026 J. Craig Venter launches genomics startup designed to boost diagnostic insights
FierceBiotech Jan 23, 2026 Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
FierceBiotech Jan 22, 2026 Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection
FierceBiotech Jan 22, 2026 Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
FierceBiotech Jan 22, 2026 Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
FierceBiotech Jan 21, 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech Jan 21, 2026 FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma